Fifth Third Bancorp
VNDA icon

Fifth Third Bancorp’s Vanda Pharmaceuticals VNDA Stock Holding History

Fifth Third Bancorp’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-153
Closed -$722 – 2778
2025
Q2 		$722 Buy
+153
New +$669 ﹤0.01% 2464
2023
Q4 		– Sell
-52
Closed -$225 – 2668
2023
Q3 		$225 Sell
52
-135
-72% -$750 ﹤0.01% 2546
2023
Q2 		$1.23K Sell
187
-282
-60% -$1.81K ﹤0.01% 2478
2023
Q1 		$3.19K Buy
469
+357
+319% +$2.51K ﹤0.01% 2463
2022
Q4 		$828 Buy
+112
New +$1.09K ﹤0.01% 2558
2022
Q1 		– Sell
-360
Closed -$6K – 2797
2021
Q4 		$6K Buy
360
+246
+216% +$4.29K ﹤0.01% 2299
2021
Q3 		$2K Buy
+114
New +$2K ﹤0.01% 2515

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Fifth Third Bancorp's VNDA Position: Q3 2025 in Review

Fifth Third Bancorp sold out of Vanda Pharmaceuticals (VNDA) in Q3 2025, closing a stake of 153 shares — an estimated $722 sold.

Fifth Third Bancorp first reported a position in VNDA in Q3 2021 and held it in 7 quarters. The position peaked at $6K in Q4 2021. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.

  • Fifth Third Bancorp reported no remaining Vanda Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Fifth Third Bancorp sold 153 Vanda Pharmaceuticals shares in Q3 2025, an estimated $722.
  • Fifth Third Bancorp first reported a position in Vanda Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • Fifth Third Bancorp's Vanda Pharmaceuticals position peaked at $6K in Q4 2021.
  • 150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.

Based on Fifth Third Bancorp's 13F filing for Q3 2025, filed 7 Nov 2025.